MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/120/0.1/20.09.24 Stock

Warrant

DE000ME1GBC8

Market Closed - Börse Stuttgart 12:51:14 2024-07-05 EDT
2.25 EUR +6.13% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/120/0.1/20.09.24
Current month-8.16%
1 month-1.75%
Date Price Change
24-07-05 2.25 +6.13%
24-07-04 2.12 +8.72%
24-07-03 1.95 -16.31%
24-07-02 2.33 -10.04%
24-07-01 2.59 +5.71%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 12:51 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1GBC
ISINDE000ME1GBC8
Date issued 2023-10-03
Strike 120 $
Maturity 2024-09-20 (77 Days)
Parity 10 : 1
Emission price 0.38
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.69
Lowest since issue 0.26
Delta0.89x
Omega 5.021
Premium1.91x
Gearing5.67x
Moneyness 1.186
Difference Strike -22.37 $
Difference Strike %-18.64%
Spread 0.01
Spread %0.43%
Theoretical value 2.315
Implied Volatility 35.40 %
Total Loss Probability 14.95 %
Intrinsic value 2.064
Present value 0.2513
Break even 145.09 €
Theta-0.03x
Vega0.01x
Rho0.02x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus